CHAPTER 8 HPV vaccines

International Journal of Gynecology and Obstetrics

Volumn 94, Issue SUPPL. 1, 2006, Pages

  Frazer, Ian H ^a  

^a NONE

Author keywords

Cervical cancer; Human papillomavirus; Vaccination

Indexed keywords

PROTEIN E6; PROTEIN E7; WART VIRUS VACCINE;

ARTICLE; CANCER GRADING; CANCER PREVENTION; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; INFECTION RISK; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VULVA CANCER; WART VIRUS;

EID: 33846589916     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(07)60014-9     Document Type: Article

References (14)

1. Ferguson M., Heath A., Johnes S., Pagliusi S., and Dillner J. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 118 6 (2006) 1508-1514
2. Frazer I. Prevention of cervical cancer through papillo-mavirus vaccination. Nat Rev Immunol 4 1 (2004) 46-55
3. Koutsky L., Ault K., Wheeler C., Brown D., Barr E., Alvarez F., et al., Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl JMed 347 21 (2002 Nov 21) 1645-1651
4. Harper D., Franco E., Wheeler C., Ferris D., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papil-lomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004 Nov 13) 1757-1765
5. Villa L., Costa R., Petta C., Andrade R., Ault K., Giuliano A., et al. Prophylactic quadrivalent human papillo-mavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
6. Harper D., Franco E., Wheeler C., Moscicli A., Romanowsli B., Roteli-Martins C., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
7. Frazer I. Human papillomavirus update: prevention of cervical cancer and genital warts through vaccination. In: Plotkin S. (Ed). Vaccines Update (2005), Elsevier Inc, Philadelphia 6
8. Mao C., Koutsky L., Ault K., Wheeler C., Brown D., Wiley D., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 1 (2006) 18-27
9. Skjeldestad F; Future II steering committee, Department of Epidemiology, SINTEF Health Research, Trondheim, Norway. Prophylactic quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Program and abstracts of the 43rd Annual meeting of the Infectious Diseases Society of America; October 6-9, 2005; San Francisco, USA. Abstract LB-8a
10. D Harper for FUTURE I Investigators. Efficacy of a Prophy-lactic Quadrivalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine for Prevention of Cervical Dysplasia and External Genital Lesions (EGL) Sattler C. Presented at: ICAAC (45th Interscience Conference on Antimicrobial Agents and Chemotherapy), December 16-19, 2005 Washington, DC. Abstract number: 3999, LB2-25
11. Schwartz TF. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old. American Society of Clinical Oncology, 2006, Annual Meeting, June 2-6, 2006 Abstract number:
12. Munoz N. for the FUTURE II Study Group. Efficacy of a quadrivalent HPV (types 6, 11, 16, 18) L1 VLP Vaccine against cervical intraepithelial neoplasia grades 1-3 and adenocarcinoma in situ: a combined analysis. Abstract for European Research Organization on Genital Infection and Neoplasia (EUROGIN), April 23-26, Paris, France. Abstract No.
13. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347 21 (2002) 1652-1661
14. Keith S Reisinger, Stan L Block, Eduardo Lazcano, Ruiwilai Samakoses. A Randomized controlled trial to evaluate the safety and immunogenicity of a quadrivalent Human papil-lomavirus (types 6, 11, 16 and 18) L1 Virus-Like-Particle vaccine in preadolescents and adolescents. Abstract presented at the European Society for Paediatric Infectious Diseases, Basel Switzerland, May 3-5, 2006. Abstract.